Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathan Papa

Showing results (81-90 of 109) with videos related to

Pageof 11
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 30, 2024
Comparison of Posttherapy 4- and 24-Hour [<sup>177</sup>Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate CancerMina Swiha, Sarennya Pathmanandavel, Nathan Papa, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 18, 2024
Development of a Visually Calculated SUV<sub>mean</sub> (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to <sup>177</sup>Lu-PSMA Therapy: Comparison with Quantitative SUV<sub>mean</sub> and Patient OutcomesMina Swiha, Nathan Papa, Zahra Sabahi, et al.
BJU International|November 28, 2024
Utility of PSA free-to-total ratio for clinically significant prostate cancer in men with a PSA level of <4 ng/mLSamuel Sii, Nathan Papa, Ting Wai Yiu, et al.
Psycho-Oncology|October 8, 2021
Self-reported lack of energy or feeling depressed 12 months after treatment in men diagnosed with prostate cancer within a population-based registryJonathan G Bensley, Haryana M Dhillon, Sue M Evans, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 18, 2022
The PRIMARY Score: Using Intraprostatic <sup>68</sup>Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer DiagnosisLouise Emmett, Nathan Papa, James Buteau, et al.
The Journal of Urology|September 5, 2025
The Blind Spot of PSMA-PET Staging? Intraductal Carcinoma of the Prostate Is Overrepresented in Patients With No Uptake Pattern on Prostate-Specific Membrane Antigen Positron Emission Tomography and High-Grade Prostate CancerDavid C Chen, Zein Alhamdani, Nathan Papa, et al.
ANZ Journal of Surgery|December 1, 2025
Outcomes of Radical Nephrectomy With Caval Tumour Thrombectomy Including a Novel Two-Stage ApproachDaniel Crisafi, Anne Hong, Nathan Papa, et al.
JAMA Network Open|November 1, 2021
Evaluation of Hypofractionated Radiation Therapy Use and Patient-Reported Outcomes in Men With Nonmetastatic Prostate Cancer in Australia and New ZealandDavid I Pryor, Jarad M Martin, Jeremy L Millar, et al.
Cancer Causes & Control : CCC|September 26, 2019
Body size and dietary risk factors for aggressive prostate cancer: a case-control studyMikaela Pal, Allison M Hodge, Nathan Papa, et al.
BJU International|November 13, 2022
Synchronous vs independent reading of prostate-specific membrane antigen positron emission tomography (PSMA-PET) and magnetic resonance imaging (MRI) to improve diagnosis of prostate cancerPaul Doan, William Counter, Nathan Papa, et al.
Pageof 11

Showing results (81-90 of 109) with videos related to

Sort By:
Pageof 11
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 30, 2024
Comparison of Posttherapy 4- and 24-Hour [<sup>177</sup>Lu]Lu-PSMA SPECT/CT and Pretherapy PSMA PET/CT in Assessment of Disease in Men with Metastatic Castration-Resistant Prostate CancerMina Swiha, Sarennya Pathmanandavel, Nathan Papa, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 18, 2024
Development of a Visually Calculated SUV<sub>mean</sub> (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to <sup>177</sup>Lu-PSMA Therapy: Comparison with Quantitative SUV<sub>mean</sub> and Patient OutcomesMina Swiha, Nathan Papa, Zahra Sabahi, et al.
BJU International|November 28, 2024
Utility of PSA free-to-total ratio for clinically significant prostate cancer in men with a PSA level of <4 ng/mLSamuel Sii, Nathan Papa, Ting Wai Yiu, et al.
Psycho-Oncology|October 8, 2021
Self-reported lack of energy or feeling depressed 12 months after treatment in men diagnosed with prostate cancer within a population-based registryJonathan G Bensley, Haryana M Dhillon, Sue M Evans, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 18, 2022
The PRIMARY Score: Using Intraprostatic <sup>68</sup>Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer DiagnosisLouise Emmett, Nathan Papa, James Buteau, et al.
The Journal of Urology|September 5, 2025
The Blind Spot of PSMA-PET Staging? Intraductal Carcinoma of the Prostate Is Overrepresented in Patients With No Uptake Pattern on Prostate-Specific Membrane Antigen Positron Emission Tomography and High-Grade Prostate CancerDavid C Chen, Zein Alhamdani, Nathan Papa, et al.
ANZ Journal of Surgery|December 1, 2025
Outcomes of Radical Nephrectomy With Caval Tumour Thrombectomy Including a Novel Two-Stage ApproachDaniel Crisafi, Anne Hong, Nathan Papa, et al.
JAMA Network Open|November 1, 2021
Evaluation of Hypofractionated Radiation Therapy Use and Patient-Reported Outcomes in Men With Nonmetastatic Prostate Cancer in Australia and New ZealandDavid I Pryor, Jarad M Martin, Jeremy L Millar, et al.
Cancer Causes & Control : CCC|September 26, 2019
Body size and dietary risk factors for aggressive prostate cancer: a case-control studyMikaela Pal, Allison M Hodge, Nathan Papa, et al.
BJU International|November 13, 2022
Synchronous vs independent reading of prostate-specific membrane antigen positron emission tomography (PSMA-PET) and magnetic resonance imaging (MRI) to improve diagnosis of prostate cancerPaul Doan, William Counter, Nathan Papa, et al.
Pageof 11